iBio (NYSEAMERICAN:IBIO) is set to announce its earnings results before the market opens on Monday, September 27th.
Shares of IBIO traded down $0.01 during midday trading on Tuesday, reaching $1.13. The stock had a trading volume of 1,019 shares, compared to its average volume of 9,751,594. iBio has a 52 week low of $1.03 and a 52 week high of $2.83. The company has a debt-to-equity ratio of 0.30, a quick ratio of 17.60 and a current ratio of 17.67. The company has a market capitalization of $246.17 million, a PE ratio of -1.85 and a beta of -6.24.
An institutional investor recently raised its position in iBio stock. Morgan Stanley increased its holdings in shares of iBio, Inc. (NYSEAMERICAN:IBIO) by 55.5% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 162,344 shares of the biotechnology company’s stock after buying an additional 57,941 shares during the quarter. Morgan Stanley owned 0.07% of iBio worth $244,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 19.96% of the company’s stock.
iBio Company Profile
iBio, Inc is a biotechnology company, which engages in the development and manufacture of biotherapeutics. Its pipeline include idiopathic pulmonary fibrosis, systemic sclerosis, and scleroderma. The firm operates through the iBio, Inc and iBio CDMO business segments. The company was founded by Robert B.
Featured Story: What is the Federal Reserve?
Receive News & Ratings for iBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iBio and related companies with MarketBeat.com's FREE daily email newsletter.